Perceptive Advisors EOLS Position
Exited3-Fund ConvergencePerceptive Advisors exited their position in Evolus, Inc. (EOLS) in Q3 2025, after holding the stock for 9 quarters.
The position was first reported in Q3 2023 and has been tracked across 9 quarterly 13F filings.
EOLS is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 11.9% of float with 5.2 days to cover, indicating significant bearish positioning against the stock.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Full company profile →Short Interest
11.9%
5.2 days to cover
Perceptive Advisors EOLS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -2,474,843 | $0 |
| Q2 2025 | Decreased | 2,474,843 | -1,654,299 | $22.8M |
| Q1 2025 | Decreased | 4,129,142 | -1,016,704 | $49.7M |
| Q4 2024 | Decreased | 5,145,846 | -210,776 | $56.8M |
| Q3 2024 | Decreased | 5,356,622 | -397,176 | $86.8M |
| Q2 2024 | Held | 5,753,798 | — | $62.4M |
| Q1 2024 | Increased | 5,753,798 | +1,790,374 | $80.6M |
| Q4 2023 | Increased | 3,963,424 | +2,477,623 | $41.7M |
| Q3 2023 | New | 1,485,801 | +1,485,801 | $13.6M |
Frequently Asked Questions
Does Perceptive Advisors own EOLS?
No. Perceptive Advisors exited their position in Evolus, Inc. (EOLS) in Q3 2025. They previously held the stock for 9 quarters.
How many hedge funds own EOLS?
3 specialist biotech hedge funds currently hold EOLS, including Tang Capital Management, Deerfield Management, EcoR1 Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy EOLS?
Perceptive Advisors's position in EOLS was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's EOLS position increasing or decreasing?
Perceptive Advisors completely exited their EOLS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EOLSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →